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The genomic profile of multiple myeloma (MM) has prognostic value by dividing patients into a good prognosis hyperdi-
ploid group and a bad prognosis nonhyperdiploid group with a higher incidence of IGH translocations. This classification,
however, is inadequate and many other parameters like mutations, epigenetic modifications, and genomic heterogeneity
may influence the prognosis. We performed a genomic study by array-based comparative genomic hybridization on a
cohort of 162 patients to evaluate the frequency of genomic gains and losses. We identified a high frequency of X chromo-
some alterations leading to partial Xq duplication, often associated with inactive X (Xi) deletion in female patients. This
partial X duplication could be a cytogenetic marker of aneuploidy as it is correlated with a high number of chromosomal
breakages. Patient with high level of chromosomal breakage had reduced survival regardless the region implicated. A higher
transcriptional level was shown for genes with potential implication in cancer and located in this altered region. Among
these genes, IKBKG and IRAK1 are members of the NFKB pathway which plays an important role in MM and is a target for
specific treatments. VC 2016 Wiley Periodicals, Inc.
INTRODUCTION
Multiple myeloma (MM) is a hematological dis-
order characterized by an uncontrolled accumula-
tion of clonal plasma cells in the bone marrow.
The prognosis is partially determined by genomic
alterations revealed by array-based comparative
genomic hybridization (aCGH) and/or fluores-
cence in situ hybridization (FISH). In contrast to
myeloid and lymphoid leukemias which display
mainly whole chromosome alterations due to
mitotic errors, MM often harbor partial genomic
alterations and translocations (Munshi and Avet-
Loiseau, 2011). This difference may be explained
by the high transcriptomic and splicing activity of
the type of cell implicated in the disease. Triso-
mies of odd chromosomes and hyperdiploidy
(HD) are considered to be associated with a good
prognosis while del(1p), dup(1q), del(13q),
del(17p), and t(4;14), associated with nonhyperdi-
ploidy (NHD), are considered as poor prognosis
markers. However, many MM show a heteroge-
neous genomic profile and alterations with an
unknown prognostic impact. In these cases, the
genetic markers provide limited prognostic infor-
mation reliability. A clinical impact of the chromo-
somal breakage level was proposed in some recent
studies, which were based on quantifying genomic
alterations, particularly those with chromosome
breaks. Indeed, structural chromosomal alterations
seem to have a poor prognostic impact and to
reflect deficiencies in genomic repair systems
(Chung et al., 2013; Przybytkowski et al., 2014).
High throughput sequencing data of MM sam-
ples show many mutations in genes known to be
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implicated in cancerogenesis but also in genes
with a role in RNA processing, protein folding or
coding for cancer testis antigens (Chapman et al.,
2011). However, the low frequency of these muta-
tions suggests that they may be passenges. Indeed,
most mutations involve weakly expressed genes
(Rashid et al., 2014). Other types of genomic alter-
ation like loss of heterozygosity (LOH) have been
linked to adverse outcome in some cancers but
their prognostic significance in MM remains
unknown (Walker and Morgan, 2006; Gronseth
et al., 2015).
The X chromosome is often altered in cancers
and carries more point mutations than other chro-
mosomes. Genetic studies of medulloblastoma
have shown a twofold increase in X gonosome
mutations compared to autosomes (J€ager et al.,
2013). Cancer-testis antigen genes on X are often
mutated in MM and their expression seems to be
related to disease progression (de Carvalho et al.,
2012). The impact of X chromosome alterations in
cancer is unknown but a correlation was shown
between the development of particular forms of
breast cancer (sporadic basal-like cancer) and loss
of inactive X (Xi) markers, sometimes with dupli-
cation of the remaining chromosome leading to a
copy number neutral loss of heterozygosity (CNN-
LOH). These alterations may result in a localized
over-expression of X chromosome genes (Richard-
son et al., 2006; Sun et al., 2015).
In this study, we used the aCGH technology on
a cohort of 162 MM patients to detect copy num-
ber variations (CNV). We focused on genomic X
profiles and evaluated the impact of X alterations




Approval was obtained from the Institutional
Review Board (Ethical Committee of the Faculty
of Medicine of the University of Lie`ge) in compli-
ance with the Declaration of Helsinki. This work
consisted of a prospective study and did not lead
to any changes in the treatment of the enrolled
patients.
Patients and Sample Preparation
Bone marrow samples and clinical data were
obtained after informed consent from patients fol-
lowed at the CHU of Lie`ge and other regional
medical centers (Table 1). Only patients with
medullar plasmocytosis over 10% based on bone
marrow smear examination were included in the
study. EasySep Human CD138 Positive Selection
Kit (Stemcells Technologies, Grenoble, France)
was used to enrich plasma cells populations. Plas-
ma cell purity evaluation was performed by cytom-
etry with CD138 antibody or morphologically by
examining Giemsa stained slides. Samples with
plasma cells purity over 80% were selected for
genomic DNA (gDNA) and RNA extraction using
AllPrep DNA/RNA extraction kit (Qiagen, Venlo,
The Netherlands) according to the manufacturer’s
instructions.
aCGH, CNV, and SNP Analysis
The plasma cells were analyzed with the Sure-
Print G3 Human CGH Microarray Kit 8x60K (Agi-
lent Technologies, Santa Clara, CA) according to
the manufacturer’s instructions, and the results
were interpreted using the Cytogenomics software
(Agilent Technologies). The arrays were scanned
with a G2565CA microarray scanner (Agilent
Technologies) and the images were extracted and
analyzed with the CytoGenomics software v2.0
(Agilent Technologies). An ADM-2 algorithm
(cutoff 6.0), followed by a filter to select regions
with three or more adjacent probes and a mini-
mum average log2 ratio of 60.25, was used to
detect copy number changes. The quality of each
experiment was assessed by the measurement of
the derivative log ratio spread with the CytoGe-
nomics software v2.0. Genomic positions were
based on the UCSC human reference sequence
(hg19) (NCBI build 37 reference sequence
assembly).
Genotyping of 25 patients from our cohort was
also performed with Genome-Wide Human SNP
array 6.0 and analyzed with the Genotyping Con-
sol 4.0 (Affymetrix, Santa Clara, CA). Unpaired
analyses were performed using 270 Hapmap files
as references. The regional CG correction parame-
ter was selected and the UCSC human reference
sequence (hg19) (NCBI build 37 reference
sequence assembly) was chosen as annotation files.
The thresholds for minimum number of markers
per segment and the minimal genomic size of a
segment were 5 and 5 Mb, respectively, in the
SNP analysis.
Gene Transcription Profiling
RNA quality control and quantification were
done with spectrophotometer ND-1000 and
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Agilent 2100 bioanalyser using RNA 6000 Nano
Kit (Agilent). Libraries were prepared using
TruSeq Stranded Total RNA Sample Prep Kit
(Illumina, Essex, UK) from 400 ng of total RNA
and following the manufacturer’s instructions.
Briefly, rRNA was depleted before purification,












Heavy chain IgA 28 17%
IgD 1 0,6%
IgG 70 43%
Light chains 32 20%
Nonsecretory 1 0,6%
Unknown 30 18%




Status Diagnosis 78 48%
Follow-up 60 37%
Unknown 24 15%
Age (years); range 75 (36–92)
Survival (months); range 29 (1–157)
Plasmocytosis (%); range 37.2 (10–94)
F, female; M, male.
Figure 1. Prevalence of genomic aberration. Bars above the x axis indicates gains and below
the x axis losses. Gains of whole chromosome most frequently involved 3, 5, 7, 9, 11, 19, and 21.
Losses most frequently involved 13, 1p, 6q, 8p, 14, and 16q. [Color figure can be viewed at
wileyonlinelibrary.com]
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fragmentation and cDNA double strand synthesis.
After 30 adenylation and ligation of adapters, DNA
fragments were enriched. The size of the library
was evaluated on an Agilent Technologies 2100
Bioanalyzer using a DNA 1000 chip (Agilent). A
size of approximately 300 bp was expected.
Libraries were run on HiSeq2000 sequencer (Illu-
mina). All DNA libraries were sequenced using an
Illumina HiSeq2000, producing 23 100 bp paired-
end reads with multiplexing. Fastq data were ana-
lyzed using the TopHat Alignment software from
Basespace (Illumina).
Reverse-Transcription and Real-Time PCR
Reverse transcription was performed on 50 ng
RNA using RevertAid H Minus First Strand cDNA
Synthesis Kit (Thermo scientific, Erembodegem,
Belgium), following the manufacturer’s instructions.
Real time PCR was performed using Kapa Sybr Fast
qPCR LightCycler 480 readymix kit (Sopachem,
Eke, Belgium). Real-time PCR reactions were car-
ried out on LightCycler 480 Real-Time PCR system
using specific primers (Table 2). The relative
expression quantification was calculated using b-2-
microglobuline as a reference gene.
Conventional and Molecular Cytogenetics
Screening for immunoglobulin heavy chain
gene (IGH) rearrangements (t(4;14)(p16;q32))
with the dual-fusion translocation probes (Abbott
Molecular, Wavre, Belgium) and 17p deletions
(LSI p53, 17p13.1) (Abbott Molecular) were per-
formed on purified plasma cells. Cell suspensions
from 120h-cultured bone marrow cells were used
retrospectively and prospectively. A minimum of
TABLE 2. Sequences of Primers Used for Real-Time Polymerase Chain Reaction
Gene name Forward primer sequence Reverse primer sequence
IRAK1 caa cgt cct tct gga tga gag gct atg ctg ctc tgg ctg ggg ct
ENOX2 gcc aga gac acc ttg gta gtg ccc a gcc tca gga cat tcg ccc caa acc
BCAP31 tgg ctt ctg agg ata ctg cgt cta gcc cgc aag agc gac tcc ta
SASH3 ccc tga gaa gat ggc gct ggc ctt ggc tgc aga gct cac tgc ctg t
RBMX ctg agc tgc tag gaa gcc cct a tga caa tgg gtt caa gct cca acg
IKBKG tcc cac agc tat gac acc gga agc gcg gac tgt gaa cgc tgg tag g
BCORL1 gga ttc gca tgt gtg gca tc cgt gag ctc cac ctt gga aa
MTMR1 tgt gga ctg gat gat gcc ttc gac tct agg gtc ctg ctg aca gag c
NSDHL cca cat ccc cta ctg ggt ggc cta tga agg tgg gct gca gct gga tga c
RBMX2 cac tgg ccc taa gaa gca cag cag c gga ttt ggg gag ctt ctg ccc ctc
XIST tcc tta gta gtc atg tct cct tag aac aac aag cct att ctt ctg ag
TABLE 3. Most Frequent Minimal Common Altered Regions
Genomic alteration Frequency (%)
del(X) 47 (only women)
dup(X)(q27q28) 21



















Figure 2. Xist expression levels in relation to X chromosome pro-
files. The expression levels of Xist were compared between female
patients with partial X deletion including the Xist locus (M126, M103,
M22, M11, M3, M4, and M7) and female patients without deletion
including this locus (M18, M36, and M119). Patients with a copy num-
ber of 1 for the Xist locus show a drastic decrease in its expression.
Four males were tested as negative controls. The b2-microglobuline
gene was used for normalization.
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20 Giemsa-banded metaphases were karyotyped
by conventional cytogenetic analyses using stan-
dard procedures. FISH using whole painting chro-
mosome probes for X (Kreatech, Diegem,
Belgium) was performed on fixed slides with
120 h-cultured bone marrow cells and selected
plasma cells.
RESULTS
Frequent X Chromosome Alterations
In our patient population, we confirmed the earli-
er observations that trisomies chromosomes 3, 5, 7,
9, 11, 19, and 21 were the most frequent whole chro-
mosomes gains (Smadja, 2001; Kumar et al., 2012).
Most monosomies involved chromosomes X (female
patients), 13, and 22. Minimal recurrent altered
regions, in decreasing order of frequency, were:
dup(1q), dup(X)(q27q28), del(16q), del(1)(p31p32),
del(1)(p11p13), del(8p), del(14)(q24q31), del(12)
(p12p13), and del(X)(p22.3q21) (Fig. 1). Complete
and partial X deletions were observed in 47%
(N 5 31) and 17% (N 5 10) of the female patients
respectively. Partial X duplication was seen in 21%
(N5 34) of the patients regardless of sex (Tables 3).
Transcriptomic evaluation of Xist in female patients
with partial X deletion showed a drastic decrease in
this noncoding gene leading to the conclusion that
the deleted chromosome is the inactive one (Fig. 2).
X deletions were not present in male tumors, proba-
bly because X nullisomy does not allow cell survival.
Genotyping of 25 patients revealed CNN–LOH
of several genomic regions but the incidence of
such alterations was quite low in our cohort and
did not involve any specific regions. CNN–LOH
of Xq25q28 was observed in three patients (two
females and one male) and was associated with
the loss of Xpter to Xq25 in the two female
patients (Table 4). Therefore, the tumors from
these two female patients lacked the Xi chromo-
some and partially duplicated the active chromo-
some. This kind of alteration could modify the
gene expression profile of this region.
X Chromosome Transcription Profile
Transcriptomic screening by RNA-seq was per-
formed on two female cases with partial X deletion
and compared to three cases without any abnor-
mality of the X chromosome. Although we could
TABLE 4. Regions Involved in CNN–LOH Detected in 25
Patients















Figure 3. Expression profiles along the X chromosome. RNA-seq performed on patients with
abnormal X profile (M12, M20, and M25) did not show any different profiles between these and
those with partial X alterations (region located to the right of the red bar) (M3 and M22). [Color
figure can be viewed at wileyonlinelibrary.com]
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not detect any significant overall difference
between the groups (Fig. 3), several genes were
selected to confirm their high transcription level
on a larger number of patients. We analyzed 10 of
them (IKBKG, IRAK1, RBMX, NSDHL, RBMX2,
MTMR1, ENOX2, BCORL1, SASH3, and BCAP31)
by RT-qPCR and detected that all of them
showed a higher transcriptional level in patients
with partial X alterations (Fig. 4). To confirm this
observation on a larger cohort we performed a
comparative analysis based on GEO-website avail-
able GEP (GSE 26760) and aCGH (GSE 26863)
data. In this cohort, IKBKG and IRAK1, both
involved in the NFKB pathway, were also over-
expressed in tumors with partial X alterations. A
similar observation was made for NSDHL,
BCAP31, and RBMX2, three genes for which a
clear link with cancer and MM has not yet been
established (Fig. 5).
Genomic X Profile and Aneuploidy
Currently, the most reliable genomic marker to
evaluate the prognosis in MM remains the detec-
tion of CNVs. We tried to establish whether the
number of alterations could be linked to a specific
X chromosome profile. Poor prognosis alterations
including del(1p), dup(1q), del(13q), del(16q),
del(17p) and t(4;14) were not correlated with the
X profiles. However, the total number of altera-
tions and alterations with an unknown prognostic
impact were significantly more frequent in
patients with partial alterations of the X chromo-
some compared to patients with X monosomy or
normal X profile (Fig. 6A). Therefore, patients
with partial X alterations have a higher incidence
of structural chromosomal alterations, while gains
and losses of whole chromosomes were not signifi-
cantly different between the three groups (Fig.
Figure 4. Expression levels of 10 Xq-linked genes analyzed together
(A) and independently (B). The average expression level in the Xq
region is higher for patients with partial X alterations (N 5 6) com-
pared to those without partial X alterations (N 5 7) (A). No signifi-
cant difference was detected when we tested each gene independently
(B). The b2-microglobuline gene was used for normalization. [Color
figure can be viewed at wileyonlinelibrary.com]
Figure 5. Expression profiles of the X-linked genes IKBKG, IRAK1, RBMX, NSDHL, and RBMX2
obtained from the GEO dataset GSE 26760. Groups were built based on X genomic profile (GSE
26863). Patients with partial X alterations (green color) overexpressed these X-linked genes com-
pared to those without partial X alterations (blue color). [Color figure can be viewed at wileyonline-
library.com]
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6B). We did not find any direct association
between the X chromosome profiles and overall
patient survival; however, our data indicated a ten-
dency to a worse outcome for patients with a par-
tial X alteration, compared to normal X profiles or
complete X losses (Fig. 7A). However, we
observed that a high level of chromosomal break-
age (more than 3 breaks) was associated with a
reduced overall survival (Fig. 7B).
DISCUSSION
MM is characterized by numerous chromosomal
rearrangements, possibly indicating the presence
of chromosomal instability. Indeed, it has been
demonstrated that DNA double strand break
repair mechanisms are impaired in tumors leading
to multiple rearrangements (Cagnetta et al., 2015;
Herrero et al., 2015). aCGH and sequencing data
have confirmed a genetic evolution of MM during
different phases of the disease, with the diagnostic
and relapse aCGH profiles being different (Bolli
et al., 2014; Keats et al., 2012).
We performed a genomic study of MM, after
positive selection of tumor cells, in order to detect
chromosomal rearrangements and to study their
clinical and biological implications. We observed
frequent rearrangements on the X chromosome.
Tumors in female MM patients frequently
showed monosomy X or a copy number of 1 from
pter to the Xq region (47 and 12% of the female
patients, respectively). The exact position on Xq
differed but was located between Xq21 and Xq25.
Genotyping of two female patients with such a
copy number profile showed a CNN–LOH of the
Xq region. In male patients, a partial duplication,
involving the same area, was observed in 28% of
patients. These alterations are too frequent and
too similar to represent passenger events and
should thus contribute to the development or pro-
gression of the MM. In our study, we found that
this recurrent X chromosome alteration was a cyto-
genetic marker associated with numerous genomic
breakpoints, maybe reflecting chromosomal insta-
bility. Interestingly, a complete duplication of the
active X has been described in basal-like breast
cancers as well as in other tumors (Sirchia et al.,
2005; Kang et al., 2015) and one study found a
globally increased expression of X-linked genes in
breast cancers with a duplication of the active X
chromosome (Richardson et al., 2006) while other
reports showed a partial reactivation of gene tran-
scription from the inactive X in some tumors
(Lose et al., 2008; Chaligne et al., 2015). The par-
tial duplication of the X long arm seems to be very
rare in other cancers and may be a characteristic of
MM.
Many chromosomal alterations have a limited
impact on gene transcription. For example, tumors
with trisomy of odd chromosomes do not show
specific transcriptomic profiles, in contrast, translo-
cations involving IGH, are linked to a specific pro-
file (Broyl et al., 2010). Indeed, processes by
which chromosome number aberrations occur are
different than those leading to structural aberra-
tions. The first type of alteration implicate deregu-
lation of protein involved in centrosome
biogenesis leading to centrosome dysfunction or
Figure 6. (A) Association between X chromosome profiles and
prognostic groups, and (B) between whole chromosome gain/loss and
structural abnormalities. There were three different groups based on
the types of alterations: poor (negative impact on prognosis which
include del(1p32), del(1p22), dup(1q21), del(8p), del(12p12p13),
del(13), (del(16q), del(17p), and dup(20q)), good (trisomy of uneven-
numbered chromosomes) and unknown (unknown impact on progno-
sis). There was a significant association between partial X alterations
and the incidence of unknown prognosis alterations. Generally these
patients seem to have more genomic alterations (A). Patients with par-
tial X alterations have more structural abnormalities than those with
complete X deletion or normal X profiles. Furthermore, the incidence
of whole chromosome gains/losses seems to be approximatively the
same between the different groups (B). [Color figure can be viewed at
wileyonlinelibrary.com]
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abnormal centrosome number as responsible for
segregation errors. The origin of the second type
of alteration is more complex, it may be partially
explained by the presence of fragile sites and
defect in double-strand break (DSB) repair (Vitre
and Cleveland, 2012). Homologous recombination
(HR) and nonhomologous end-joining (NHEJ)
are important pathways in the DSB repair
system. Deregulation of genes involved in these
pathways such as ATM, NBN, XRCC4-6, PRKDC,
DCLREC1C, and LIG4 leads to a higher level of
chromosomal breakage with partial losses or gains
of genomic material (Krem et al., 2015). These
chromosomal fragments could be translocated and
submitted to other gene expression regulation pro-
cesses, resulting in a more important impact on
the phenotype and prognosis of partial X alteration
as compared to complete X monosomy. Based on
transcriptomic data, we observed that partial
duplication of the active X chromosome does not
have any significant impact on the transcription of
the complete gene set from this region. However,
a more specific data analysis based on our cohort
and on a GEP online-available data set indicated a
higher transcriptomic level of some Xq genes that
are known to be involved in pathways activated in
MM. Among these genes, IKBKG and IRAK1
belong to the NFKB pathway, which plays an
important role in MM progression, treatment resis-
tance and is targeted by proteasome inhibitors.
Interestingly, a global study of genomic rearrange-
ments in human cancers identified NFKB path-
way genes, including IRAK1 and IKBKG, as
frequently involved in amplified regions (Berou-
khim et al., 2010). Therefore, these two genes are
likely to be very relevant for MM progression and
treatment response, as demonstrated in other can-
cers (Aigelsreiter et al., 2012; Wee et al., 2015).
Other genes that are located in this region are also
biologically relevant. Indeed, ENOX2 has been
associated with tumor cell migration (Wang et al.,
2011; Zeng et al., 2012), BCAP31 with anti-cancer
immune response (Sankaranarayanan et al., 2015)
and RBMX/RBMX2 code for RNA-binding pro-
teins with possible roles in gene expression and
DNA repair (Adamson et al., 2012). These data
therefore indicate that the simultaneously
increased expression of several genes on Xq proba-
bly plays a role in signaling pathway activation
and in the biology of MM cells, most probably
in advanced disease with high chromosomal
instability.
X chromosome alterations might thus constitute
a predictive marker for response to some targeted
drug. However, this hypothesis needs to be evalu-
ated in a large prospective study. An aCGH analy-
sis or FISH study with probes targeting the Xp
and Xq telomeric regions could easily detect the
partial duplication of the active X chromosome.
Conventional karyotype would be less accurate
due to the difficulty in recognizing the break-
points. Indeed, there was no abnormality identifi-
able as a partial X chromosome when we analyzed
the karyotypes of two patients. Thus, the distal
Xq seems to be translocated to an unidentified
autosome (Supporting Information Fig. 1).
Figure 7. Overall survival in relation to presence of partial X altera-
tions (A) and the number of structural aberrations (B). We performed
aCGH at diagnosis of 70 patients. Based on X chromosome
profiles, there was no statistical difference in OS between the groups
with or without partial X alterations (A). Patients with more than three
structural abnormalities had reduced overall survival compared to these
with three or less structural abnormalities. P value (log rank) 5 0.008
(B). [Color figure can be viewed at wileyonlinelibrary.com]
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Moreover, low proliferation rates often lead to
non-informative karyotypes.
Even if we did not find any outcome association
with X chromosome changes, partial X alterations
were associated with a higher number of chromo-
somal breakages. We demonstrated that patients
with more than three chromosomal breaks, regard-
less of the region where they occurred, had a
decreased overall survival. These results show the
importance of whole genome screening and the
benefit of aCGH for patients with multiple
myeloma.
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